Source: Getty Images Clinicians should have a standard approach for discussing the risk of adverse events associated with immune checkpoint inhibitors, researchers say. The most common immune-related ...

Researchers from the National Defense Medical Center in Taiwan have identified an increased risk of psoriasis in patients ...

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and ...

Researchers think they've figured out why cancer treatments that harness a person's immune system to fight a tumor can cause ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but many patients with metastatic cancer develop resistance. Understanding the mechanisms behind this resistance is ...

Patients with metastatic RCC who are assigned to the control arms of ICI trials are not consistently given ICIs after their ...

Researchers at the University of Michigan Rogel Cancer Center have discovered a key reason why some cancers do not respond to ...

The most important takeaway from the study is that these data suggest that CD47 is an attractive target for drug development.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib ...

Some patients being treated with immune checkpoint inhibitors, a type of cancer immunotherapy, develop a dangerous form of heart inflammation called myocarditis.

Patients with cancer who receive immune checkpoint inhibitors (ICIs) have more than twice the risk for developing psoriasis compared with those who receive other treatments. Researchers conducted a ...